Key Highlights

● Investors positioned ahead of Oct. 24 Phase 3 data on intismeran, Moderna's personalized cancer Vaccine developed with Merck.

● A second tailwind: Moderna's Nasdaq-100 entry takes effect Oct. 9, replacing Warner Bros. Discovery.

● Vaccine stocks were a major theme, with Vaxcyte soaring on strong late-stage trial results.

Moderna rallied on Monday, Oct. 5, as investors lined up ahead of late-stage results for its personalized cancer vaccine at ESMO and its imminent move into the Nasdaq-100.

Building positions before a big readout

Moderna (NASDAQ:MRNA) climbed sharply on Monday and ranked among the top gainers in the S&P 500. Accounts of the exact gain varied, but all showed a strong advance.

A key reason is what lies ahead. On Oct. 24, Phase 3 data from the INTerpath-001 trial of intismeran, Moderna's personalized cancer vaccine developed with Merck, are due to be presented at the ESMO congress, one of the biggest meetings in cancer medicine. Investors have been positioning ahead of that presentation.

What intismeran is

Intismeran is an individualized treatment. It uses Moderna's messenger RNA technology to instruct the body to make proteins matching features of a patient's own tumour, with the aim of Training the immune system to recognise and attack cancer cells. Merck is Moderna's partner on the programme.

Because the readout is still weeks away, Monday's buying reflects anticipation rather than any new trial data.

Nasdaq-100 entry adds a second tailwind

The cancer story is not the only support. Moderna joins the Nasdaq-100 effective Oct. 9, taking the place of Warner Bros. Discovery, as announced on Oct. 2. Funds that track that index will need to own Moderna shares, which tends to bring extra Demand around the date of the change.

Together, the two events have kept the stock in focus. Moderna shares have soared this year, putting it among the biggest large-cap winners of 2026.

A vaccine-heavy day

Vaccines were a major theme on Monday. Vaxcyte (NASDAQ:PCVX) soared after its VAX-31 pneumococcal vaccine met all of its prespecified main goals in the pivotal OPUS-1 trial, holding up against Pfizer's (NYSE:PFE) Prevnar 20 and Merck's Capvaxive. Smaller names Novavax (NASDAQ:NVAX) and Emergent BioSolutions (NYSE:EBS) jumped on reports of a suspected plague case at a Russian research institute, which remains unconfirmed.

The rest of health care was weaker. The sector was the S&P 500's softest at midday, with Merck the worst performer in the Dow and Bristol-Myers Squibb (NYSE:BMY) sliding after Leerink Partners downgraded it.

The broader market was firm. The Nasdaq Composite rose 286.45 points to a record close of 27,477.31, and the Nasdaq-100 hit a record 31,076.44. The S&P 500 climbed 51.23 points to 7,773.95, just shy of its summer record, and the Dow Jones Industrial Average rose 90.94 points to 51,267.90.

That happened even as the 10-year Treasury Yield rose to its highest close since 2002. The ISM services survey showed prices paid at their highest since July 2022. But Friday's jobs report, showing only 29,000 jobs added in September, sharply reduced bets on another Fed rate hike in October.

Mohamed El-Erian said of the jobs data: "This will reinforce the impact of recent Fedspeak in calming expectations about an October rate hike."

Oil fell too, with Brent settling at $100.32 a barrel, as a G7 plan to release emergency reserves eased Supply worries.

What to watch

Two dates stand out for Moderna: Oct. 9, when it formally joins the Nasdaq-100, and Oct. 24, when the INTerpath-001 Phase 3 data on intismeran are scheduled for presentation at ESMO.

For the wider market, minutes from the Fed's September meeting are due on Wednesday, Oct. 7, at 2 p.m. ET. PepsiCo reports Thursday and Delta Air Lines Friday, bank Earnings begin on Oct. 13, and the Fed meets again on Oct. 27–28.